Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES W RANDALL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1295814952
CMS profile
240808
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$106,726.17

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES W RANDALL

NPI 1295814952 · CMS profile ID 240808

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295814952?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES W RANDALL, NPI 1295814952, CMS profile ID 240808. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295814952?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHARLES W RANDALL, NPI 1295814952, CMS profile ID 240808. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295814952?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHARLES W RANDALL, NPI 1295814952, CMS profile ID 240808, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1295814952?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $106,726.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $17.8110/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939327 CMS
ABBVIE INC. $23.3510/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418529 CMS
Lilly USA, LLC $30.5510/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917942039 CMS
ABBVIE INC. $95.5710/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418527 CMS
Celgene Corporation $32.3410/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939261 CMS
Janssen Biotech, Inc. $116.6110/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886662073 CMS
Janssen Scientific Affairs, LLC $12.2810/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274377 CMS
Lilly USA, LLC $42.5010/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917941401 CMS
Celgene Corporation $5.5710/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939325 CMS
ABBVIE INC. $18.6410/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418525 CMS
ABBVIE INC. $117.3210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418523 CMS
Nestle HealthCare Nutrition Inc. $16.5010/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902793849 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.0410/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959690457 CMS
Janssen Biotech, Inc. $19.8410/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886662067 CMS
Janssen Scientific Affairs, LLC $204.9010/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274203 CMS
Janssen Scientific Affairs, LLC $130.0010/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274209 CMS
Janssen Scientific Affairs, LLC $3.0010/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274217 CMS
ABBVIE INC. $3.4710/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418521 CMS
ABBVIE INC. $2,875.0010/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418519 CMS
ABBVIE INC. $18.1009/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418517 CMS
ABBVIE INC. $124.9909/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418515 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.8409/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955789813 CMS
Ardelyx, Inc. $18.6209/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925730769 CMS
ABBVIE INC. $6.7909/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418511 CMS
ABBVIE INC. $2,875.0009/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418513 CMS
Celgene Corporation $11.8209/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939321 CMS
Janssen Scientific Affairs, LLC $4,375.0009/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274177 CMS
Janssen Scientific Affairs, LLC $639.5409/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274183 CMS
Janssen Scientific Affairs, LLC $744.4009/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274191 CMS
Janssen Scientific Affairs, LLC $122.0909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274195 CMS
ABBVIE INC. $15.9009/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418509 CMS
PFIZER INC. $29.7509/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949362547 CMS
ABBVIE INC. $205.9609/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418505 CMS
ABBVIE INC. $74.1009/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418507 CMS
GENZYME CORPORATION $16.8109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740813 CMS
Celgene Corporation $3.5609/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939323 CMS
Janssen Scientific Affairs, LLC $130.0008/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274257 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2308/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955789809 CMS
ABBVIE INC. $14.0908/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418503 CMS
Celgene Corporation $6.6408/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939319 CMS
Janssen Scientific Affairs, LLC $130.0008/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274171 CMS
Janssen Biotech, Inc. $23.2108/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886662079 CMS
ABBVIE INC. $86.6608/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418499 CMS
ABBVIE INC. $10.6808/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891418501 CMS
Janssen Scientific Affairs, LLC $4,375.0008/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274221 CMS
Janssen Scientific Affairs, LLC $409.1208/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274229 CMS
Janssen Scientific Affairs, LLC $1,703.4008/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274235 CMS
Janssen Scientific Affairs, LLC $145.9008/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274241 CMS
Janssen Scientific Affairs, LLC $112.5508/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887274249 CMS
Braintree Laboratories, Inc. $16.9908/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898420243 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110,273.57 191
PY2020 $39,730.85 125
PY2021 $26,236.64 145
PY2022 $106,726.17 232
PY2023 $135,356.15 277
PY2024 $205,458.64 321
PY2025 $125,557.11 248

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $94,037.09 51
PY2024 Principal investigator $47,709.00 20
PY2023 Principal investigator $154,977.00 6
PY2022 Principal investigator $50,195.40 10
PY2021 Principal investigator $182,633.25 34
PY2020 Principal investigator $194,758.00 48
PY2019 Recipient $1,727.58 8
PY2019 Principal investigator $145,901.68 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $2,786.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609127
Principal investigator 1 Genentech, Inc. $1,065.00 11/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609144
Principal investigator 1 Genentech, Inc. $2,895.00 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609148
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284299
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284420
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284449
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284507
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284789
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285200
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285292
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285474
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285545
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285593
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285696
Principal investigator 1 Genentech, Inc. $1,065.00 10/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609140
Principal investigator 1 Genentech, Inc. $1,806.00 10/16/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609136
Principal investigator 1 Genentech, Inc. $1,065.00 10/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609132
Principal investigator 1 F. Hoffmann-La Roche AG $15,758.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609106
Principal investigator 1 F. Hoffmann-La Roche AG $2,360.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609110
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285161
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285208
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285435
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285601
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285665
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285726
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285822
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285878
Principal investigator 1 F. Hoffmann-La Roche AG $10,226.00 07/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609123
Principal investigator 1 Eli Lilly and Company $943.09 07/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CLINIC OF SAN ANTONIO
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883448
Principal investigator 1 F. Hoffmann-La Roche AG $4,416.00 07/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609114
Principal investigator 1 F. Hoffmann-La Roche AG $14,416.00 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY RESEARCH OF AMERICA LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211609118
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284131
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284634
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284668
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285107
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285317
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285362
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285537
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285571
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285674
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 05/12/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285775
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284056
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284642
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175284736
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285129
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285146
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285457
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285508
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285618
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285837
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Gastroenterology Rsrch Of America Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175285960